AbLearning™ - Episode 3: Chimeric Antigen Receptor T Cell Therapy 

AbLearning™ Educational Program hosted by Abnova.
Chimeric antigen receptor (CAR) T cell therapy has stirred a hot debate in clinic since the first CAR T cell therapy for ALL got approval from FDA in August 2017. Let's get into know this treatment and realize how it works.
Any questions? Feel free to contact us.
www.abnova.com/aboutus/contac...
Follow us on the social media!
Facebook: / abnova1
LinkedIn: / 504542
Twitter: / abnova1

Наука